Supernus & Catalent Enter Supply Agreement
Catalent Pharma Solutions and Supernus Pharmaceuticals recently announced they have entered into an agreement in which Catalent is the supplier of Trokendi XR extended-release capsules for Supernus. Supernus developed Trokendi XR using its own advanced drug delivery technology and transferred its formulation to Catalent for commercial manufacturing.
“Supernus selected Catalent as our commercial supply partner based on their extensive experience in manufacturing extended-release products, the long-standing relationship we have had with them, and a proven track record of high quality,” said Jack Khattar, Chief Executive Officer, President and Director of Supernus.
“We offer customers integrated solutions that include both proprietary drug delivery technologies and advanced supply solutions for oral controlled release development and commercial products, added Barry Littlejohns, President of Catalent’s Advanced Delivery Technologies business. “We are pleased to have been selected by Supernus to work on this unique epilepsy product.”
Trokendi XR is a novel, oral, extended-release, once-daily formulation of topiramate for the treatment of epilepsy. Supernus recently received approval from the FDA and launched the product in the US market. Trokendi XR delivers an extended-release form of topiramate, one of the most effective anti-epilepsy drugs.
Trokendi XR is a convenient once per day alternative to current immediate-release formulation products, which require patients to administer their medication multiple times per day.
Catalent Pharma Solutions is the global leader in development solutions and advanced drug delivery technologies, providing world-wide clinical and commercial supply capabilities for drugs, biologics, and consumer health products. For more information, visit www.catalent.com.
Total Page Views: 1189
